GlassScriptPhysician profile
Yiran Jiang
NPI 1811484983
$7,225.62
in general payments reported to CMS, 2019-2025
31 companies · $3,575 in 2025
The $3,575 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $748 · 2024: $2,903 · 2025: $3,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,984 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,983.65 |
| Education | $241.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.74 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $821.35 | 2023-2025 | |
| Ucb, INC. | $809.46 | 2023-2025 | Cimzia, Bimzelx |
| Amgen INC. | $773.09 | 2023-2025 | Krystexxa, Tavneos, Evenity |
| Janssen Biotech, INC. | $488.64 | 2023-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $470.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $345.87 | 2023-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $283.94 | 2024-2025 | Lupkynis |
| Lilly USA, LLC | $281.02 | 2023-2025 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $217.76 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Sandoz INC. | $194.47 | 2023-2025 | Hyrimoz, Jubbonti |
| Sobi, INC | $162.37 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $162.22 | 2023-2025 | Orencia |
| Glaxosmithkline, LLC. | $150.49 | 2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $122.01 | 2023-2025 | Strensiq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $113.69 | 2023-2025 | Actemra, Rituxan |
| Fresenius Kabi USA, LLC | $92.50 | 2024-2025 | Idacio |
| Invivyd INC | $91.55 | 2024-2025 | Pemgarda |
| Depuy Synthes Sales INC. | $81.01 | 2024-2025 | Orthovisc, Monovisc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.11 | 2024-2025 | Spevigo |
| Radius Health, INC. | $62.61 | 2025 | Tymlos |
| Tersera Therapeutics LLC | $58.78 | 2024 | Quzyttir |
| Kyowa Kirin, INC. | $54.34 | 2024-2025 | Crysvita |
| Genzyme Corporation | $48.58 | 2023-2024 | |
| Bioventus LLC | $41.73 | 2025 | Durolane |
| Almatica Pharma LLC | $31.55 | 2025 | Teriparatide |
| US Oncology Corporate, INC. | $26.51 | 2025 | |
| Biocon Biologics INC | $24.76 | 2023 | Hulio |
| Tonix Medicines, INC. | $18.18 | 2025 | Tonmya |
| Organon LLC | $14.82 | 2024 | |
| Fidia Pharma USA INC. | $14.42 | 2025 | Triluron, Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiran Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.